Literature DB >> 7452476

Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase.

O Lockridge, N Mottershaw-Jackson, H W Eckerson, B N La Du.   

Abstract

The enzyme in human serum that rapidly hydrolyzes diacetylmorphine (heroin) to 6-acetylmorphine is identified in this report as serum cholinesterase (EC 3.1.1.8, acylcholine acylhydrolase; also called pseudocholinesterase or butyrylcholine esterase). The rate of heroin hydrolysis was measured spectrophotometrically at 245 nm using highly purified serum cholinesterase. The turnover number was 500 mumol of heroin hydrolyzed per min per mumol active site. The product was identified spectrophotometrically and by thin-layer chromatography to be 6-acetylmorphine. There appeared to be marked product inhibition of heroin hydrolysis, as 6-acetylmorphine (Ki = 0.015 mM) bound 7 times more tightly than heroin (Ki = 0.11 mM). Purified human serum arylesterase did not hydrolyze heroin. Purified serum cholinesterase accounted for all the observed heroin hydrolysis by whole serum. The genetic variants of human serum cholinesterase, silent and atypical cholinesterase, were also tested. Serum from a person identified as having silent cholinesterase did not hydrolyze heroin. Purified atypical cholinestearase hydrolyzed heroin, but the binding was less tight (Km = 0.45 mM) than with usual cholinesterase (Km = 0.11 mM). The possibility that heroin potency may be influenced by serum cholinesterase genotype or activity level remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7452476

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  26 in total

1.  The influence of solvent composition on global dynamics of human butyrylcholinesterase powders: a neutron-scattering study.

Authors:  F Gabel; M Weik; B P Doctor; A Saxena; D Fournier; L Brochier; F Renault; P Masson; I Silman; G Zaccai
Journal:  Biophys J       Date:  2004-05       Impact factor: 4.033

2.  Serum paraoxonase activity is associated with variants in the PON gene cluster and risk of Alzheimer disease.

Authors:  Porat M Erlich; Kathryn L Lunetta; L Adrienne Cupples; Carmela R Abraham; Robert C Green; Clinton T Baldwin; Lindsay A Farrer
Journal:  Neurobiol Aging       Date:  2010-10-27       Impact factor: 4.673

3.  Fundamental reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of heroin.

Authors:  Yan Qiao; Keli Han; Chang-Guo Zhan
Journal:  Biochemistry       Date:  2013-08-30       Impact factor: 3.162

Review 4.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 5.  The metabolic serine hydrolases and their functions in mammalian physiology and disease.

Authors:  Jonathan Z Long; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2011-06-23       Impact factor: 60.622

Review 6.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

7.  Population pharmacokinetics of heroin and its major metabolites.

Authors:  Elisabeth J Rook; Alwin D R Huitema; Wim van den Brink; Jan M van Ree; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 8.  Clinical significance of esterases in man.

Authors:  F M Williams
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

9.  Binding features of diacetylmorphine (heroin) in whole blood and in blood fractions.

Authors:  I Barni Comparini; E Gaggelli; N Marchettini; G Valensin
Journal:  Biophys J       Date:  1985-08       Impact factor: 4.033

10.  Stability of heroin, 6-monoacetylmorphine, and morphine in biological samples and validation of an LC-MS assay for delayed analyses of pharmacokinetic samples in rats.

Authors:  Jessica M Jones; Michael D Raleigh; Paul R Pentel; Theresa M Harmon; Daniel E Keyler; Rory P Remmel; Angela K Birnbaum
Journal:  J Pharm Biomed Anal       Date:  2012-11-15       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.